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Abstract: Background: The prevalence of type 2 diabetes is on the increase worldwide, and it
represents about 90% of adults who are diagnosed with diabetes. Overweight and obesity, lifestyle,
genetic predisposition and gut microbiota dysbiosis have been implicated as possible risk factors in
the development of type 2 diabetes. In particular, low intake of dietary fibre and consumption of
foods high in fat and sugar, which are common in western lifestyle, have been reported to contribute
to the depletion of specific bacterial taxa. Therefore, it is possible that intake of high dietary fibre
may alter the environment in the gut and provide the needed substrate for microbial bloom. Aim:
The current review is a systematic review and meta-analysis which evaluated the role of dietary fibre
in modulating gut microbiota dysbiosis in patients with type 2 diabetes. Methods: This is a systematic
review and meta-analysis of randomised controlled trials which relied on the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) framework. Electronic searches were
conducted using EBSCOHost with links to Health Sciences Research Databases, EMBASE and Google
Scholar. The reference lists of articles were also searched for relevant studies. Searches were conducted
from date of commencement of the database to 5 August 2020. The search strategy was based on
the Population, Intervention, Comparator, Outcomes, Studies (PICOS) framework and involved the
use of synonyms and medical subject headings (MesH). Search terms were combined with Boolean
operators (OR/AND). Results: Nine studies which met the inclusion criteria were selected for the
systematic review and meta-analysis, and four distinct areas were identified: the effect of dietary fibre
on gut microbiota; the role of dietary fibre on short-chain fatty acids (SCFAs); glycaemic control; and
adverse events. There was significant difference (p < 0.01) in the relative abundance of Bifidobacterium
with a mean difference of 0.72 (95% CI, 0.56, 0.89) between the dietary fibre group compared with
placebo. In relation to the meta-analysis for SCFAs, while there was significant difference (p = 0.02)
between the dietary fibre group and placebo with a standardised mean difference of 0.5 (95% CI,
0.08, 0.91) regarding total SCFAs, the differences were not significant (p > 0.05) in relation to acetic
acid, propionic acid and butyric acid. There was only significant improvement (p = 0.002) with
respect to glycated haemoglobin with a mean difference of −0.18 (95% CI, −0.29, −0.06) between the
dietary fibre group and placebo group. Differences between the two groups were not significant
(p > 0.05) in relation to fasting blood glucose and homeostatic model assessment of insulin resistance
(HOMA-IR). Furthermore, there were no significant differences between the two groups in subjects
who reported adverse events. It is possible that the promotion of SCFA producers in greater diversity
and abundance by dietary fibre in this review led to improvement in glycated haemoglobin, partly
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due to increased glucagon-like peptide-1 (GLP-1) production. In addition, Bifidobacterium lactis has
been reported to increase glycogen synthesis, decrease expression of hepatic gluconeogenesis genes,
improve translocation of glucose transport-4 and promote glucose uptake. It is also possible that the
reduction in body weight of participants in the intervention group compared with control may have
contributed to the observed improvement in glycated haemoglobin. Conclusion: This systematic
review and meta-analysis have demonstrated that dietary fibre can significantly improve (p < 0.05)
the relative abundance of Bifidobacterium, total SCFAs and glycated haemoglobin. However, dietary
fibre did not appear to have significant effect (p > 0.05) on fasting blood glucose, HOMA-IR, acetic
acid, propionic acid, butyric acid and adverse events.
Keywords: type 2 diabetes; dietary fibre; gut microbiota; dysbiosis; short-chain fatty acids; glycated
haemoglobin; fasting blood glucose; adverse events
1. Introduction
The prevalence of type 2 diabetes is on the increase globally, and it represents about 90% of
adults who are diagnosed with diabetes [1,2]. The World Health Organisation [3] has reported an
increase from an estimated 108 million in 1980 to 422 million adults living with type 2 diabetes in 2014.
The prevalence of type 2 diabetes is predicted to reach 642 million by the year 2040 [4]. Diabetes as
a condition can have significant impact on mortality and morbidity including acute and long-term
complications [5]. There is evidence that diabetes is a major risk factor in the development of kidney
dysfunction, retinopathy, neuropathy and cardiovascular diseases [6]. Overweight and obesity, lifestyle,
genetic predisposition and gut microbiota dysbiosis have been implicated as possible risk factors in
the development of type 2 diabetes [6]. For example, low intake of dietary fibres and intake of foods
high in fat and sugar, which are common in western lifestyle, have been reported to contribute to the
depletion in the abundance of specific bacterial taxa and the diversity of gut microbial community [7].
It is possible that gut microbiota dysbiosis may influence the metabolic and functional pathways in the
gut which are involved in the development of type 2 diabetes [6].
2. Description of the Intervention
An understanding of the pathophysiology of type 2 diabetes and the various management
approaches is crucial in reducing the risks of diabetes and its complications. In particular, the use
of dietary interventions including dietary fibre has been promoted by researchers and practitioners
involved in diabetes care and management. However, there appears to be inconsistencies in what is
considered to be a dietary fibre [8]. In 2008, the Scientific Advisory Committee on Nutrition (SACN) [9]
defined dietary fibre as non-starch polysaccharides (NSP). The definition of dietary fibre was revised
in 2015 to include all carbohydrates that are neither digested nor absorbed in the small intestine and
have some degree of polymerisation of three or more monomeric units and lignin [10]. Thus, the
components of dietary fibre include total fibre, NSP, fibre components from cereal, fruits and vegetables,
polydextrose, oligosaccharides (including fructo-oligosaccharides, galacto-oligosaccharides and inulin),
lignin and soluble fibres (including pectin and guar gum) [8–10]. According to Makki et al. [7], dietary
fibre can be subdivided into polysaccharides (NSP), resistant starch, and resistant oligosaccharides.
The subdivision can also be in the form of insoluble and soluble fibres [7].
3. How the Intervention Might Work
There is evidence that diets play a significant role in modulating gut microbiota in terms of its
composition and in the production of short-chain fatty acids (SCFAs) [11]. However, our current
understanding of the exact relationships between the human gut microbiome and disease remains
limited [12]. It has been reported that the carbohydrates that are not digested and absorbed in the
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small intestine undergo fermentation by the community of commensal bacteria in the colon, which
results in the formation of SCFAs, some of which are absorbed into the blood and used as sources
of energy [10,13]. The SCFAs are mainly acetic acid, propionic acid and butyric acid, and they also
regulate the host metabolism and inflammation [14]. SCFAs stimulate the secretion of gastric inhibitory
polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in adipocytes, leading to
reduced fat accumulation [14]. In addition, the micro-organisms that reside in the gastrointestinal
tract have been implicated in health and disease [11]. In relation to bacterial taxonomy of the human
gut microbiota, the four main phyla are Actinobacteria, Bacteroidetes, Firmicutes and Proteobacteria,
and these are essential for the host metabolism and physiological regulation [2,6,15]. The healthy
balance of the microbes in the gut (eubiosis) may be disrupted, leading to imbalance or impaired gut
microbiota distribution (dysbiosis), which have been shown to contribute to insulin resistance in type
2 diabetes [6,7]. For example, many factors such as diet, lifestyle, gut permeability have been known to
affect the composition of the gut microbiota [6].
Poor dietary habits can lead to intestinal dysbiosis, such as alterations in the balance of the different
bacterial phyla, including overgrowth of Proteobacteria and/or reduction in Bacteroidetes [16]. There is
evidence that the proliferation of some bacteria species of the Proteobacteria phylum may lead to
energy disequilibrium among the different bacteria species, suppression of the growth of other bacteria
species and the development of diseases, including type 2 diabetes [16]. Therefore, the consumption of
high dietary fibre may alter the environment in the gut and provide the needed substrate for microbial
growth and proliferation, and the production of SCFAs [7]. SCFAs are essential sources of energy and
are involved in regulating host metabolism, immune system and the proliferation of cells [7]. SCFAs
can be used as sources of energy in the colonocytes, but can also be transported to the peripheral
circulation through the portal vein to the liver and peripheral tissues. Therefore, poor dietary fibre
consumption may not only reduce bacteria diversity in the gut, but also reduces SCFA production and
a shift towards the utilisation of less favourable substrates, such as dietary and endogenous protein
sources, by the gut microbiota [7]. The fermentation of proteins and amino acids by the microorganisms
in the gut can lead to reduced production of total SCFAs and butyrate as well as increased production
of cytotoxic and proinflammatory metabolites that contribute to the development of chronic diseases,
including type 2 diabetes [7].
4. Why It Is Important to Do This Review
Although an association between higher intake of dietary fibre and reduced incidence of type 2
diabetes has been indicated, the results from different studies are not consistent [10]. Furthermore,
studies have revealed that non-digestible oligosaccharides may affect the community of bacteria that
make up the gut microflora, and their effect on health is an evolving area of research [10]. Previous
systematic reviews on gut microbiota and type 2 diabetes have focused on the broad subjects of
dietary and/or lifestyle interventions [17] or probiotics and faecal microbial transplantation [6] and not
primarily on dietary fibre. To our knowledge, we have not found any meta-analysis on the effect of
dietary fibre on gut microbiota in patients with type 2 diabetes.
4.1. Aim
The current review is a systematic review and meta-analysis which evaluated the role of dietary
fibre in modulating gut microbiota dysbiosis in patients with type 2 diabetes.
4.2. Methods
This is a systematic review and meta-analysis of randomised controlled trials which relied on the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework [18].
4.3. Types of Studies
Only randomised controlled studies were included in this review.
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4.4. Types of Participants
The participants were people with type 2 diabetes, or in some studies, the control subjects did not
have type 2 diabetes.
4.5. Types of Interventions
The interventions were dietary fibre including a macrobiotic diet.
4.6. Types of Outcome Measures
The following were the outcome measures of interest:
Relative abundance of gut microbiota (genera only): Bifidobacterium, Lactobacillus, Roseburia,
Bacteroides, Ruminococcus, and Clostridium.
Short-chain fatty acids (SCFAs): total SCFA, acetic acid, propionic acid, butyric acid.
Glycaemic parameters: glycated haemoglobin (HbA1c), fasting blood glucose (FBG), homeostatic
model assessment of insulin resistance (HOMA-IR).
Adverse events: total adverse events, diarrhoea, bloating, constipation, abdominal pain.
4.7. Search Methods for Identification of Studies
Electronic searches were conducted using EBSCOHost with links to Health Sciences Research
Databases (encompassing Academic Search Premier, MEDLINE, Psychology and Behavioral
Sciences Collection, APA PsycInfo, CINAHL Plus with Full Text and APA PsycArticles databases).
Other electronic databases searched were EMBASE and Google Scholar. The reference lists of articles
were also searched for relevant studies. Searches were conducted from date of commencement of
database to 5 August 2020. The search strategy was based on the Population, Intervention, Comparator,
Outcomes, Studies (PICOS) framework [19] involving the use of synonyms and medical subject headings
(MesH) (Table 1). Search terms were combined with Boolean operators (OR/AND). The searches were
conducted independently by two researchers (OO; OOO) and cross checked by the fourth researcher
(X.W.). Differences were resolved through consensus. Articles retrieved through the electronic database
searches were exported to EndNote (Analytics, Philadelphia, PA, USA) to remove the duplicates.
Table 1. Search Terms and Search Strategy.















































Nutrients 2020, 12, 3239 5 of 21
4.8. Data Collection and Analysis
4.8.1. Selection of Studies
Studies were included based on a set of inclusion and exclusion criteria and relied on the PRISMA




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart
on selection and inclusion of studies.
Inclusion criteria: studies selected were those involving patients with type 2 diabetes (in some
studies, patients without type 2 diabetes were used as control, however, the focus in these studies was
on the intervention involving only patients with type 2 diabetes); above 18 years of age; dietary fibre as
intervention; and gut microbiota, glycaemic parameters, short-chain fatty acids and adverse events as
outcomes of interest.
Exclusion criteria: studies involving participants below 18 years of age, patients with type 1
diabetes, and pre-diabetes or gestational diabetes were excluded. Furthermore, studies involving
animal models and probiotics were also excluded.
4.8.2. Data Extraction and Management
Data from the selected articles were extracted by two researchers (X.W.; Q-Q.F.) and cross-checked
by the other two researchers (OO; OOO). For the meta-analysis data, the authors of the selected articles
were contacted for the original data where possible. Changes from baseline for the intervention were
compared with the control in all the parameters analysed [20]. The Engauge Digitizer [21] was used to
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extract data for the genus Bifidobacterium from the graphs in the studies of Medina-vera et al. [22]
and Pedersen et al [23]. Units of measurements were converted to mmol/L for fasting blood
glucose and percentage (%) for glycated haemoglobin and relative abundance of Bifidobacterium,
as necessary. Furthermore, median and 1st–3rd quartiles were converted to means and standard
deviations, respectively.
4.8.3. Assessment of Risk of Bias and Quality of Included Studies
The risk of bias for the included studies was assessed using a domain based assessment
tool [20]. The domains evaluated included the random sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants and personnel (performance bias), blinding of
outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting
(reporting bias), and other bias [20]. The process was carried out using Review Manager 5.3 software [24].
In addition, the Critical Appraisal Skills Programme [25] checklist for randomised controlled trials was
used to assess the quality of the included articles.
4.8.4. Data Analysis
The meta-analysis was carried out using Review Manager (RevMan) 5.3 software [24]. In addition,
sensitivity analysis was conducted by removing one study at a time from the meta-analysis in order
to assess the level of consistency of the results. The assessment of heterogeneity was by means of I2
statistic [20], and p < 0.10 was taken as the level of statistical significance of heterogeneity. The fixed
effects model and mean difference were used for the meta-analysis. However, for short-chain fatty
acids data, these were converted into standardised mean difference (SMD) due to the use of different
measurement scales in the outcome of interest and the random effects model was used for the analysis.
4.8.5. Effect Size
The overall effect of the intervention in relation to statistical significance was based on p < 0.05,
and the results of the meta-analysis were presented as forest plots.
5. Results
Nine studies which met the inclusion criteria were selected for the systematic review and
meta-analysis (Figure 1). The characteristics of the studies included are shown in Table 2. While three of
these studies were conducted in Italy [26–28], one study each was carried out in Norway [29], Japan [30],
Mexico [22], UK [23], Canada [31] and China [13]. All the studies were randomised controlled trials
with parallel design, except one which was a randomised cross-over study [29].
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Table 2. The description and characteristics of included studies.
Citation/Country of Study Study Type Sample Details Mean Age (Years) Aim Interventions Results






n = 25 63.1 (41–73)
To evaluate the prebiotic
effect of inulin-type fructans
on faecal microbiota and







separated the 6 weeks
of treatment.
A daily supplement of
inulin-type fructans induced
a moderate, but significant
increase in faecal levels of
bifidobacteria, total SCFA,
acetic acid and propionic acid
in patients with T2D.




Ma-Pi 2 diet: n = 21;
Control diet: n = 19. 66




macrobiotic Ma-Pi 2 diet or a
control diet recommended by
Italian professional societies
for T2D treatment—to correct
gut microbiota dysbiosis in
T2D patients.
Fibre-rich macrobiotic
Ma-Pi 2 diet versus
control diet.
21 days of treatment.
The Ma-Pi 2 diet was
associated with a greater
reduction in FBG.
Body weight changes (mean
± SD) kg:
Ma-Pi 2 diet: −5.6 ± −1.0
Control diet: −2.7 ± −0.6




GOS: n = 27;
Placebo: n = 25.
GOS: 55 ± 11
Placebo: 54 ± 12.
To assess the effects of GOS
on glycaemic control and gut
microbiotas and metabolites





GOS restored the abundance
of Bifidobacteriaceae.
However, GOS did not have
a significant effect on glucose
tolerance.













DF: n = 28
Placebo: n = 25
DP: 50.4 ± 8.7
Placebo: 49.8 ± 10.6













shown to improve insulin
sensitivity.
There were no significant
differences in the levels of
glucose between groups.
Patients with T2D following
the DP showed significant
reductions in specific
biochemical parameters
compared with the placebo
group: AUCs for glucose.
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Table 2. Cont.
Citation/Country of Study Study Type Sample Details Mean Age (Years) Aim Interventions Results






GOS: n = 14; Placebo:
n = 15.
GOS: 56.7 ± 1.6;
Placebo: 58.1 ± 1.7.
To compare the effects of
prebiotic supplementation
with placebo treatment for 12









12 weeks of treatment.
Prebiotic fibre
supplementation had no




Body weight changes (mean
± SEM) kg:
GOS: 0.6 ± 0.1
Placebo: 0.1 ± 0






PGX®: n = 147
Placebo: n = 143.
PGX®: 56.2 ± 8.6
Placebo: 53.4 ± 9.9.
To examine the adjunct effect
of the soluble viscous fibre
PolyGlycopleX® (PGX®) on




52 weeks of treatment.
The butyrate producer
(Roseburia) was significantly
increased in the PGX® group.






Body weight changes: mean
(95% CI) kg
PGX®: −3.87 (−1.75 to −6.0)
Placebo: −1.62 (0.56 to −3.80)





Ma-Pi 2 diet: n = 25;
Control diet: n = 26
Ma-Pi 2 diet: 67 ±
8.163
Control diet: 65 ±
7.284
To evaluate the effect of
different dietary
approaches—the macrobiotic
Ma-Pi 2 diet compared with
standard diets recommended
for patients with T2D.
Fibre-rich macrobiotic
Ma-Pi 2 diet versus
control diet:
21 days of treatment.
There was significantly
greater reduction in fasting
blood glucose, HbA1c, and
insulin resistance in those
patients receiving the Ma-Pi 2
diet compared with those in
the control diet group.
Body weight changes (mean
± SD) kg
Ma-Pi 2 diet: −4.9 ± 0.4
Control diet: −3.97 ± 0.08
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Table 2. Cont.
Citation/Country of Study Study Type Sample Details Mean Age (Years) Aim Interventions Results







Ma-Pi 2 diet: n = 17
Control diet: n = 23.
Ma-Pi 2 diet: 65 ± 8.89
Control diet: 64 ± 8.15
To investigate whether the
benefits of the original 21-day
intensive dietary
interventions extended
beyond the original MADIAB
trial duration and into
everyday life.
Fibre-rich macrobiotic




The Ma-Pi diet was
associated with a higher
percentage reduction in
HbA1c.




median (1st–3rd quartile) kg
Ma-Pi 2 diet: −1.46 (−4.59;
0.78)
Control diet: 0.72 (−2.4; 3.26)








Control: n = 16.
High dietary fibre:
58.4 ± 6.2.
Control: 59.7 ± 6.0;
To characterise the dynamics
of the gut microbiota and its
impact on glucose





A select group of
SCFA-producing strains was
promoted by dietary fibres,
and most other potential
producers were either
diminished or unchanged in
patients with T2D.
Body weight changes (mean
± SEM) kg:
High dietary fibre: −2.99 ±
−0.16
Control: −1.09 ± −0.13
Abbreviations: AUCs—areas under the curve; DP—dietary portfolio; FBG—fasting blood glucose; GOS—galacto-oligosaccharide; HbA1c—glycated haemoglobin; kg—kilogram;
Ma-Pi 2—macrobiotic diet; PGX®—PolyGlycopleX®; T2D—type 2 diabetes; SCFAs—short-chain fatty acids.
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5.1. Risk of Bias in Included Studies
The risks of bias in the included studies are shown in Figure 2a,b. Of the studies, 100% showed a
low risk of bias in relation to blinding of participants and personnel, incomplete outcome data, selective
reporting and other potential sources of bias (Figure 2a). On the other hand, less than 75% of the
studies showed a low risk of bias in respect of blinding of outcome assessment, while less than 25% of
the studies had a low risk of bias in terms of random sequence generation and allocation concealment.
All the studies included in this review demonstrated either a low risk of bias or an unclear risk of bias
in all the domains of assessment (Figure 2b).
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5.2. Effects of Interventions
Based on the systematic review and meta-analysis, four distinct areas were identified: the effect of
dietary fibre on gut microbiota; the role of dietary fibre on short-chain fatty acids; glycaemic control;
and adverse events.
5.3. The Effect of Dietary Fibre on Gut Microbiota
The effects of dietary fibre on gut microbiota at the genus level are outlined in Table 3. According
to Zhao et al. [13], the acetate-producing Bifidobacterium pseudocatenulatum was one of the most
significantly promoted SCFA producers, and the enhancement of these positive responders reduced
the producers of compounds, such as indole and hydrogen sulphide, which could be metabolically
detrimental. There is evidence that patients with type 2 diabetes demonstrated intestinal dysbiosis based
on the presence of increased levels of Prevotella copri [22]. However, following dietary intervention
with functional foods, there was a significant modification of the faecal microbiota compared with
control diet through the promotion of alpha diversity and an increased abundance of specific bacteria,
independently of antidiabetic drugs [22].
However, Reimer et al. [31] found that the abundance of Lactobacillus spp. was greater in the
control group, and although Faecalibacterium prausnitzii increased in both the dietary fibre and control
groups, it was more profound in the control group (p = 0.038). Furthermore, there was a higher level for
Collinsella spp. in the dietary fibre group compared with control. However, there were no significant
differences in alpha or beta diversity [31]. According to Birkeland et al. [29], in the dietary fibre group,
there was moderate changes in the faecal microbiota composition (1.5%, p = 0.045), and the effect was
most prominent on operational taxonomic units (OTUs) of Bifidobacterium adolescentis, followed by
OTUs of Bacteroides.
There was no significant effect on total bacteria, Lactobacillus, Roseburia, Enteroacteriaceae,
Clostridium leptum or Clostridium coccoides groups following prebiotic fibre treatment in the study
conducted by Pedersen et al. [23].
The meta-analysis of Bifidobacterium, which was the only genus we were able to extract data for,
involved two studies and 80 participants. There was significant difference (p < 0.01) in the relative
abundance of Bifidobacterium with a mean difference of 0.72 (95% CI, 0.56, 0.89) between the dietary
fibre group compared with placebo (Figure 3).
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Table 3. The effect of dietary fibre on gut microbiota at the genus level.
Citations Bacteroides Clostridium Lactobacillus Ruminococcus Roseburia Bifidobacterium
Birkeland et al. [29].





Not Applicable Not Applicable Not Applicable Not Applicable
A bifidogenic effect was most
prominent, with the highest
positive effect on operational
taxonomic units (OTUs) of
Bifidobacterium adolescentis




























increased by intake of GOS
compared with the baseline.




Pedersen et al. [23]. Not Applicable
Prebiotic treatment had












Prebiotic treatment had no
significant effect on
Bifidobacterium or any of the
other bacteria measured






Soare et al. [27]. Not Applicable Not Applicable Not Applicable Not Applicable Not Applicable Not Applicable
Soare et al. [28]. Not Applicable Not Applicable Not Applicable Not Applicable Not Applicable Not Applicable
Zhao et al. [13]. Not Applicable Not Applicable Not Applicable Not Applicable Not Applicable
Bifidobacterium
pseudocatenulatum was one
of the most significantly
promoted SCFA producers
Abbreviations: DP—dietary portfolio; GOS—galacto-oligosaccharide; PGX®—PolyGlycopleX®; SCFA—short-chain fatty acid.
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5.4. The Role of Dietary Fibre on Short-Chain Fatty Acids
In the study by Birkeland et al. [29], while the intervention (dietary fibre) group showed a
significant increase in faecal concentrations of total SCFA (p = 0.04), acetic acid (p = 0.02), and propionic
acid (p = 0.04) as compared to control group, there was no significant difference in relation to butyric
acid between the treatments (p = 0.19) or on the overall microbial diversity [29].
In terms of the relationship between microbiota and the SCFA (acetic, propionic, butyric and
valeric acid), a general trend was that acetic acid was positively related to operational taxonomic units
(OTUs) that increased with the prebiotic fibre (Birkeland et al., 2020). On the other hand, the opposite
trend was observed for the OTUs that declined with the prebiotic treatment, and the prebiotic affected
OTUs of Bifidobacterium adolescentis were negatively related to butyric acid [29].
In relation to the meta-analysis for total SCFAs, two studies were included and involved
95 participants (Figure 4a). In contrast, 3 studies each and 145 participants, respectively, were included
in the meta-analysis for acetic acid, propionic acid and butyric acid (Figure 4b–d). While there was a
significant difference (p = 0.02) between the dietary fibre group and placebo with a standardised mean
difference of 0.5 (95% CI, 0.08, 0.91) with respect to total SCFAs (Figure 4a), the differences were not
significant (p > 0.05) in relation to acetic acid (Figure 4b), propionic acid (Figure 4c) and butyric acid
(Figure 4d). Following sensitivity analysis, differences between the dietary fibre group and placebo
were only significant (p = 0.04) for propionic acid and butyric acid when the study of Gona et al. [30]
was removed, respectively, from the meta-analysis for each metabolite.
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5.5. Glycaemic Control
According to Candela et al. [26], when patients with type 2 diabetes were randomised to follow
the high-fibre diet or the control diet, there was significant reduction of fasting blood glucose and
postprandial blood glucose in both diet groups. However, the difference was significantly higher
for patients following the high-fibre diet compared with those following the control diet [26]. In the
study by Soare et al. [27], the dietary fibre group showed a significantly greater reduction in glycated
haemoglobin (p = 0.002) levels than the control group. Furthermore, Soare et al. [28] found that
although both the dietary fibre and control diet groups maintained their benefits beyond the 21 days,
the dietary fibre group resulted in greater improvement in glycaemic control following intensive
monitoring over a 6-month period.
However, differences between the intervention and control groups were not significantly different
with respect to glucose variables in the study conducted by Medina-Vera et al. [22]. Similarly,
at 52 weeks, while patients with type 2 diabetes on intervention diet had a greater relative reduction
in glycated haemoglobin from baseline (–3.19%) compared to control group (–0.57%) (p = 0.02); the
differences between the groups were not statistically significant [31].
In terms of the meta-analysis, while 6 studies were included for fasting blood glucose with
508 participants (Figure 5a), glycated haemoglobin had 8 studies with 599 participants (Figure 5b),
and HOMA-IR had 5 studies with 216 participants (Figure 5c). However, there was only significant
difference (p = 0.002) with respect to glycated haemoglobin with a mean difference of −0.18 (95% CI,
−0.29, −0.06) between the dietary fibre group and placebo group (Figure 5b). Differences between
the two groups were not significant (p > 0.05) in relation to fasting blood glucose (Figure 5a) and
HOMA -IR (Figure 5c). Following a sensitivity analysis, the results for fasting blood glucose and
HOMA-IR did not change. However, a difference between the dietary fibre group and placebo was not
significant (p = 0.19) for glycated haemoglobin when the study of Soare et al. [27] was removed from
the meta-analysis.
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5.6. Adverse Events
There were no adverse side effects reported by the participants in the study by Pedersen et al. [23].
Furthermore, Gonai et al. [30] observed that galacto-oligosaccharides were well-tolerated, and no
participant reported any severe adverse events. In the study by Reimer et al. [31], there were no
significant differences (p > 0.05) between the two groups in subjects who reported adverse events
(Table 4).
Table 4. The most common adverse events reported over 52 weeks in participants allocated to PGX®
or placebo.
PGX® (n = 103) Placebo (n = 104)
Total adverse events 580 525
Most common events:
Diarrhoea/loose stool 150 61
Cold/flu-like symptoms 56 71
Abdominal bloating 35 29
Abdominal pain/cramps 37
Constipation 17 48
Headache/sinus pain 27 45
Abbreviations: PGX®—PolyGlycopleX®. Data from Reimer et al. [31].
6. Discussion
The results of this systematic review and meta-analysis have shown that there were significant
improvements (p < 0.05) in glycated haemoglobin, total SCFAs and the relative abundance of
Bifidobacterium in the dietary fibre group compared with the control group. In contrast, differences
between the two groups were not statistically significant (p > 0.05) in relation to fasting blood glucose,
HOMA-IR, acetic acid, propionic acid, butyric acid and adverse events.
Some of the findings of this review would appear to confirm the results of an earlier systematic
review by Houghton et al. [17] which assessed the effectiveness of dietary intervention on gut
microbiota in adults with type 2 diabetes. Houghton et al. [17] also found significant improvement
in glycated haemoglobin in the intervention group compared to control, but found no significant
differences (p > 0.05) between the two groups in relation to fasting blood glucose, HOMA-IR and
in the relative abundance of Bifidobacterium. The difference between this current review and the
review by Houghton et al. [17] with respect to Bifidobacterium may be due to the type of dietary
intervention, which was primarily dietary fibre in our review. Houghton et al. [17] observed that there
were significant changes in the gut microbiota at the other taxonomic levels including phylum, family,
genus and species. Fallucca et al. [32] have also reported that the Ma-Pi 2 diet has resulted in significant
improvements in metabolic control, including fasting blood glucose and glycosylated haemoglobin in
patients with type 2 diabetes in different continents.
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Although several studies have reported the association between dysbiosis and type 2 diabetes,
the results are often varied and inconsistent [6,33]. Dysbiosis has been reported to be positively
associated with plasma glucose levels and the occurrence of type 2 diabetes [34]. It has been found
that dysbiosis in the gut microbiota in patients with type 2 diabetes is characterised by a reduction
in biodiversity [15,17]. Ebrahimzadeh Leylabadlo et al. [6] have also noted the findings of previous
studies and demonstrated that type 2 diabetes was found to be associated with a reduction in the
proportion of Firmicutes. Furthermore, the microbiome is characterized by the reduction of several
butyrate-producing bacterial species including Clostridium, Eubacterium rectale, Faecalibacterium
prausnitzii, Roseburia intestinalis, Roseburia inulinivorans and an enrichment of opportunistic
pathogens [6]. The genera of Bifidobacterium, Bacteroides, Faecalibacterium, Akkermansia and
Roseburia have been negatively associated with type 2 diabetes, while the genera of Ruminococcus,
Fusobacterium, and Blautia have been positively associated with type 2 diabetes [35].
The mechanism by which changes in the community of gut microbiota modulates metabolic
control is still evolving. However, a number of possible mechanisms have been documented including
altering levels of glucagon-like peptide-1, lipopolysaccharides, inflammation and SCFAs [17]. The role
of gut microbiota in type 2 diabetes involves microbial dysbiosis which harms the integrity of the
intestinal wall and allows the translocation of bacteria, lipopolysaccharides, a metabolic endotoxemia
from the gut lumen to the systemic circulation [2,36]. Furthermore, the endotoxemia causes low-grade
inflammation, autoimmunity, and oxidative stress, which may lead to beta cell destruction or insulin
resistance [2]. In other words, changes in the profile of gut microbiota cause gut permeability and
loss of energy homeostasis, which leads to endotoxemia, low-grade inflammation, hyperglycaemia,
hyperlipidaemia, obesity and insulin resistance [2,36]. Factors such as ethnicity, environment and
socio-economic variables may influence the community of gut microbiota in terms of their abundance
and diversity [15]. Other factors such as the use of broad spectrum antibiotics and changes in the
quality of the diet including reduction in dietary fibre consumption could lead to disequilibrium in the
community of gut microbiota [36]. Therefore, dysbiosis can elicit increased inflammatory activation
through an increase in immune response to lipopolysaccharides, and this process contributes to the
development of insulin resistance and type 2 diabetes [36].
The gut microbiota has been reported to influence energy levels, blood glucose and the effectiveness
of pharmacological interventions [17]. While most of the insoluble fibres (e.g., cellulose and
hemicellulose) are not fully digested by the gut bacteria and thus have a faecal bulking effect,
most soluble fibres are fermented by the gut bacteria to produce metabolites, including SCFAs [7].
However, resistant oligosaccharides and most soluble NSPs are viscous and are able to form a gel
structure in the intestinal tract, which can delay absorption of glucose and lipids, thus regulating
post-prandial metabolism [7]. The gut microbiota and diet are two very useful components that keep
the integrity of the gut intact and the production of intestinal mucus [7]. Thus, reduced intake of
dietary fibre can lead to a reduction in the mucus layer and increase the risk of infection and the
development of chronic inflammatory disease [7].
In the study by Candela et al. [26], which highlighted microbiota dysbiosis in patients with
type 2 diabetes in contrast to healthy subjects, both diets were found to be effective in modulating
gut microbiome dysbiosis in patients with type 2, leading to a bloom in ecosystem diversity in
health-promoting SCFA producers, such as Faecalibacterium, Roseburia, Lachnospira, Bacteroides
and Akkermansia. However, it was the high-fibre diet and not the control diet that was effective in
counteracting the increase in possible pro-inflammatory groups, such as Collinsella and Streptococcus
in the gut ecosystem and showing the potential to reverse pro-inflammatory dysbiosis in patients with
type 2 diabetes, and possibly explaining the greater efficacy in improving the metabolic control [26].
In the current review, Gonai et al. [30] found that galacto-oligosaccharides (GOS) can ameliorate
dysbiosis in patients with type 2 diabetes, and the long-term use of GOS may be an effective strategy
for managing this condition. For example, while the abundance of Bifidobacteriaceae and the diversity
of intestinal microbiota were significantly lower in patients with diabetes than in healthy subjects,
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Bifidobacteriaceae was significantly restored in patients with diabetes after consumption of GOS,
although glucose tolerance did not improve during the period [30]. With respect to the dietary fibre,
there was significant relationship between changes in gut microbiota components and changes in
biochemical parameters [26]. It is possible that the promotion of SCFA producers in greater diversity
and abundance by dietary fibre in this review led to improvement in glycated haemoglobin, partly due
to increased glucagon-like peptide-1 (GLP-1) production [13]. In addition, Bifidobacterium lactis has
been reported to increase glycogen synthesis, decrease expression of hepatic gluconeogenesis genes,
improve translocation of glucose transport-4 and promote glucose uptake [35]. It is also possible that
the reduction in body weight of participants in the intervention group due to the higher dietary fibre
content of the diet [28] compared with control may have contributed to the observed improvement
in glycated haemoglobin [31]. For example, in the study by Reimer et al. [31], at 52 weeks, only
the high-fibre group had a significant decrease in body weight. In addition, Zhao et al. [13] and
Soare et al. [27,28], found that the high-fibre group showed greater reduction in body weight than the
control group. Weight loss ranging from 5–10% has been reported to improve glycated haemoglobin
and obesity-related metabolic risk factors [31,37,38], while weight gain leads to deterioration in glycated
haemoglobin levels [31,39]. A number of studies have also demonstrated that the consumption of a
soluble, viscous fibre supplement can improve glycaemic control, including glycated haemoglobin in
patients with type 2 diabetes [40–42].
The physico-chemical properties of dietary fibre are significant in influencing the function of the
gastrointestinal (GI) tract including digestion, nutrient bio-accessibility, microbial fermentation and
glycaemic control [43]. In addition, dietary fibre can have effect on the GI transit time and increased
digesta viscosity, which can affect the flow of food [40,43]. The relative amounts and proportions
of the components of dietary fibre such as cellulose, hemicellulose, pectin, lignin and water vary
depending on the botanical source and the maturity of the plant tissue [43]. These properties have a
significant effect on the physiology of digestion and gut function, including nutrient bio-accessibility,
rate of gastric emptying and transit time, inhibition of flow, mixing efficiency of digesta, effects of gut
microbiota and glycaemic control [43–45].
It would appear that a number of mechanisms are involved in the physiological effects of dietary
fibre on macronutrient digestion, and the mechanism that predominates may be determined by a range
of factors, including polysaccharide composition, the physical state of the fibre source, whether the
fibre has been processed and the presence of other variables in foods such as lipids, which can also
influence gut function [43].
Dietary fibres that are water soluble have been shown to reduce fasting plasma cholesterol in
human subjects by modifying bile salt metabolism [43,46]. Soluble fibres have also been reported to
lower plasma cholesterol levels by direct binding of polysaccharides to bile salts [43,47]. Another process
of improving glycaemic control with a soluble fibre supplement is by significantly increasing the
viscosity of chyme [40,48]. The increase in viscosity slows the interaction of enzymes and the nutrients,
and this slows the breakdown of complex nutrients into absorbable forms and slows the absorption of
glucose [40,47].
However, a major mechanism that has been identified in the control of blood glucose in patients
with type 2 diabetes is the role of dietary fibre in physically encapsulating/entrapping nutrients,
thus slowing the rate of digestion of plant tissues and reducing the rise in blood glucose [43,49].
The structural integrity of plant tissue can also be affected by food processing, and this can influence
bio-accessibility and digestion [43]. For example, it has been reported that starch that is encapsulated
with a leguminous cell is protected from digestion in the small intestine and produces a low glucose
response compared to non-encapsulated starch [43].
The ranking of different carbohydrate foods can also be based on their glycaemic index [50,51].
Therefore, foods that have low glycaemic index, such as lentils, beans and oat, provide gradual supply
of glucose to the blood and thus ensure a more sustained insulin release [50]. Soluble fibre is closely
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related to the concept of glycaemic index by delaying the absorption of dietary carbohydrates due to
its viscous and gel-forming properties, thus reducing postprandial glucose excursions [52].
7. Limitation of the Review
Although nine studies were included in the overall meta-analysis, the studies included in the
meta-analysis for SCFAs and gut microbiota were no more than three and two studies, respectively,
and this could limit the wider application of the findings. Therefore, more studies are required in
this area of research. In addition, despite the use of the random effects model in the analysis of
short-chain fatty acids, the high heterogeneity of the studies included may have also affected the results
of the meta-analysis.
8. Conclusions
This systematic review and meta-analysis have demonstrated that dietary fibre can significantly
improve (p < 0.05) the relative abundance of Bifidobacterium, total SCFAs and glycated haemoglobin.
However, dietary fibre did not appear to have a significant effect (p > 0.05) on fasting blood glucose,
HOMA-IR, acetic acid, propionic acid, butyric acid and adverse events.
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